Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life-Reference-Cited by-同舟云学术

Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life

Published:2022-04 Issue: Volume:Volume 15 Page:505-515
ISSN:1178-6965
Container-title:Journal of Asthma and Allergy
language:en
Short-container-title:JAA

Author:

Menzella Francesco^ORCID,Fontana Matteo,Contoli Marco^ORCID,Ruggiero Patrizia,Galeone Carla,Capobelli Silvia,Simonazzi Anna,Catellani Chiara,Scelfo Chiara^ORCID,Castagnetti Claudia,Livrieri Francesco,Facciolongo Nicola

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy

Reference33 articles.

1. First biologic for allergy-related asthma. FDA Consum. 2003: 5.

2. Selecting the right biologic for your patients with severe asthma

3. Biologic therapy in the management of asthma

4. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations

5. Omalizumab for asthma in adults and children

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type 2 severe asthma: pathophysiology and treatment with biologics;Expert Review of Respiratory Medicine;2024-07-02

2. Effets indésirables des biothérapies de l’asthme sévère;Revue des Maladies Respiratoires;2024-05

3. Long-term safety, durability of response, cessation and switching of biologics;Current Opinion in Pulmonary Medicine;2024-03-01

4. Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients?;Pragmatic and Observational Research;2024-03

5. Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study;BMC Pulmonary Medicine;2023-12-05